Related references
Note: Only part of the references are listed.Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses
Boning Liu et al.
MABS (2018)
Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
Elie Dheilly et al.
MOLECULAR THERAPY (2017)
Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy
Yuting Huang et al.
JOURNAL OF THORACIC DISEASE (2017)
Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer
Yun Yang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma
Zhenyu Xiao et al.
CANCER LETTERS (2015)
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
Emily C. Piccione et al.
MABS (2015)
Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency
Yun Yang et al.
MABS (2015)
Macrophages are critical effectors of antibody therapies for cancer
Kipp Weiskopf et al.
MABS (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
A CD47-blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity
Valerie R. Wiersma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Signal-regulatory protein α from the NOD mouse binds human CD47 with an exceptionally high affinity - implications for engraftment of human cells
Lai Shan Kwong et al.
IMMUNOLOGY (2014)
Antibodies directed against receptor tyrosine kinases Current and future strategies to fight cancer
Benedicte Fauvel et al.
MABS (2014)
Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity
Whitney Shatz et al.
MABS (2013)
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Kipp Weiskopf et al.
SCIENCE (2013)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Jagath R. Junutula et al.
CLINICAL CANCER RESEARCH (2010)
Functions and molecular mechanisms of the CD47-SIRPα signalling pathway
Takashi Matozaki et al.
TRENDS IN CELL BIOLOGY (2009)
Effector mechanisms of therapeutic antibodies against ErbB receptors
Matthias Peipp et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation
Sanjay Khandelwal et al.
TRANSFUSION (2007)
Share Paper
